| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | 0.041 | 0.8 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |